checkAd
    Startseite > Aktien > Oryzon Genomics S.A > Nachrichten
    Oryzon Genomics S.A Aktie
    1,9180
     
    EUR
    -1,84 %
    -0,0360 EUR
    Letzter Kurs 02.05.24 Lang & Schwarz
    1,8920
     
    EUR
    482 STK
    Geldkurs 02.05.24
    1,9440
     
    EUR
    482 STK
    Briefkurs 02.05.24
    ISIN: ES0167733015 · WKN: A2ACV2 · Spanien

    Neueste Nachrichten

    ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
    22.04.24 · globenewswire · Oryzon Genomics S.A
    ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
    08.04.24 · globenewswire · Oryzon Genomics S.A
    ORYZON to Provide Corporate Progress Updates at Several Events in April
    05.04.24 · globenewswire · Oryzon Genomics S.A
    ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
    26.02.24 · globenewswire · Oryzon Genomics S.A
    ORYZON to Provide Corporate Progress Updates at Several Events in February-March
    05.02.24 · globenewswire · Oryzon Genomics S.A
    ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
    19.01.24 · globenewswire · Oryzon Genomics S.A
    ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)
    05.01.24 · globenewswire · Oryzon Genomics S.A
    ORYZON to Provide Corporate Progress Updates at Several Events in January
    03.01.24 · globenewswire · Oryzon Genomics S.A
    ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
    21.11.23 · globenewswire · Oryzon Genomics S.A
    ORYZON Announces Last Patient Last Visit in its Phase IIb PORTICO Study for Borderline Personality Disorder (BPD)
    07.11.23 · globenewswire · Oryzon Genomics S.A
    ORYZON to Provide Corporate Progress Updates at Several Events in November
    06.11.23 · globenewswire · Oryzon Genomics S.A
    ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
    27.10.23 · globenewswire · Oryzon Genomics S.A